Clinical TrialJun 29, 2026, 08:01 AM
4D Molecular Therapeutics Completes 4FRONT-2 Phase 3 Enrollment Early
AI Summary
4D Molecular Therapeutics announced the completion of global enrollment for its 4FRONT-2 Phase 3 clinical trial evaluating 4D-150 for wet age-related macular degeneration (wet AMD). Enrollment was completed approximately four months ahead of initial projections and was over-enrolled, reflecting strong interest from investigators and patients. The company expects 52-week topline data for 4FRONT-2 in H2 2027, with 4FRONT-1 data anticipated in H1 2027, and plans to initiate a Phase 3 trial for diabetic macular edema in Q3 2026.
Key Highlights
- 4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections.
- 4FRONT-2 over-enrolled with anticipated N>500 patients.
- Final patient randomization for 4FRONT-2 expected in Q3 2026.
- 4FRONT-2 52-week topline data is expected in H2 2027.
- 4FRONT-1 52-week topline data is expected in H1 2027.
- Phase 3 trial in diabetic macular edema to initiate in Q3 2026.
Price Impact
More from FDMT